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A B S T R A C T   
Background: Frequently SARS-CoV-2 results in mild or moderate disease with potentially lower concentrations of 
antibodies compared to those that are hospitalised. Here, we validated an ELISA using SARS-CoV-2 trimeric spike 
glycoprotein, with targeted detection of IgG, IgA and IgM (IgGAM) using serum and dried blood spots (DBS) from 
adults with mild or moderate disease. 
Methods: Targeting the SARS-CoV-2 trimeric spike, a combined anti-IgG, IgA and IgM serology ELISA assay was 
developed using 62 PCR-confirmed non-hospitalised, mild or moderate COVID-19 samples, ≥14 days post 
symptom onset and 624 COVID-19 negative samples. The assay was validated using 73 PCR-confirmed non- 
hospitalised, mild or moderate COVID-19 samples, ≥14 days post symptom onset and 359 COVID-19 negative 
serum samples with an additional 81 DBSs. The assay was further validated in 226 PCR-confirmed non-hospi-
talised, mild or moderate COVID-19 samples, ≥14 days post symptom onset and 426 COVID-19 negative clinical 
samples. 
Results: A sensitivity and specificity of 98.6% (95% CI, 92.6–100.0), 98.3% (95% CI, 96.4–99.4), respectively, 
was observed following validation of the SARS-CoV-2 ELISA. No cross-reactivities with endemic coronaviruses or 
other human viruses were observed, and no change in results were recorded for interfering substances. The assay 
was stable at temperature extremes and components were stable for 15 days once opened. A matrix comparison 
showed DBS to correlate with serum results. Clinical validation of the assay reported a sensitivity of 94.7% (95% 
CI, 90.9–97.2%) and a specificity of 98.4% (95% CI, 96.6–99.3%). 
Conclusions: The human anti-IgGAM SARS-CoV-2 ELISA provides accurate and sensitive detection of SARS-CoV-2 
antibodies in non-hospitalised adults with mild or moderate disease. The use of dried blood spots makes the assay 
accessible to the wider community.   
1. Introduction 
The COVID-19 pandemic resulting from severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection was declared an in-
ternational public health emergency in early 2020 (Organization WH, 
2020a). Unlike previous coronavirus infection outbreaks, such as SARS- 
CoV and Middle East Respiratory Syndrome, the lack of rapid, overt 
symptomatic presentation in 80% of patients (Organization WH, 2020b; 
Organization WH, 2020c), has meant seroconversion rather than mo-
lecular testing has become an established method to understand SARS- 
CoV-2 epidemiology. 
Asymptomatic or even mild infection cases represent a challenge for 
in vitro SARS-CoV-2 diagnostic assays, both in terms of understanding 
the required sensitivity and specificity (Deeks et al., 2020), and for 
obtaining samples from molecular tested positive patients. In addition, 
as seroconversion to different immunoglobulin types is not a synchro-
nous process, testing of the major humoral immune system components 
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may be preferable to limiting assessment to individual isotypes such as 
IgG, IgA & IgM (IgGAM). 
Here we describe the validation of an ELISA, utilising recombinant 
SARS-CoV-2 trimeric spike glycoprotein (Wrapp et al., 2020; Watanabe 
et al., 2020), with targeted detection of IgG, IgA and IgM antibodies in 
non-hospitalised adults with mild or moderate disease. 
2. Materials & methods 
2.1. Samples 
Serum and Dried Blood Spot (DBS) samples were collected from 
consenting non-hospitalised polymerase chain reaction (PCR) positive 
adults, presenting with mild or moderate symptoms of COVID-19 dis-
ease, ≥14 days post symptom onset, and from individuals COVID-19 
negative (Organization WH, 2020c; Prevention CfDCa, 2020; Shah 
et al., 2020). Samples collected prior to the pandemic (pre December 
2019) were deemed COVID-19 negative. Serum samples were stored at 
− 20 ◦C and thawed before analysis. 
Residual anonymised samples were used in this study from several 
sources. For the specificity and sensitivity analysis residual samples 
were from commercial sources (BioIVT, approved by Western Institu-
tional Review Board - IRB20161665; TCS Bioscience approved by The 
Diagnostics Investigational Review Board- IRB112015–01.1; anony-
mised normal samples provided by Plasma Services Group were 
collected with patient consent via an FDA registered blood establish-
ment (registration number 3005275238)) and further residual samples 
collected in accordance with REC 2002/201; South Birmingham 
Research Ethics Service. For dried blood spot comparison, residual 
anonymised samples were collected from University of Birmingham 
(REC 2002/201; South Birmingham Research Ethics Service). For cross 
reactivity analysis, samples were provided by the Amsterdam University 
Medical Center of the University of Amsterdam, the Netherlands 
(approved by the Medical Ethics Committee; MEC 07/182MEC 07/182). 
Samples were used in accordance with the world medical association 
declaration of Helsinki Ethical principles for Medical Research involving 
human subjects. 
2.2. ELISA 
A stabilised trimeric spike protein preparation with 95% purity 
(Watanabe et al., 2020), assessed by silver stain, was coated onto ELISA 
plates (Nunc High Bind, Thermo Fisher Scientific, Loughborough, UK) at 
1.0 μg/mL in PBS for 24 h. Plates were blocked using 2% BSA blocking 
reagent (Sigma, Gillingham, UK) prepared in PBS-0.1% Tween 20 and 
incubated for 1 h at room temperature. Subsequently, plates were 
washed three times with PBS-1% Tween +0.08% Proclin300 and air 
dried before packing in airtight in aluminium-coated packs with drying 
agent (IDS, Gateshead, UK). 
High, low, negative and cut-off calibrator controls were generated 
using COVID-19 negative pooled normal human and specific human 
monoclonal IgG1, IgA and IgM anti-SARS-CoV-2 S glycoprotein 
(CR3022, Absolute Antibodies, Upper Heyford, UK) (Huo et al., 2020). 
100 μL of either the controls (neat dilution), calibrator (neat dilution) or 
serum samples (diluted 1/40) were added to the coated plate and 
incubated for 30 min at room temperature. The plate was then washed 
three times with PBS-0.1% Tween and purified horseradish peroxidase 
(HRP)-labelled polyclonal rabbit antibody to human IgG, IgA, IgM 
(DAKO, USA) (100 μL) was added to each well and then incubated for a 
further 30 min at room temperature (RT). The plate was washed a 
further three times and substrate solution containing 3,3′5,5′-tetrame-
thylbenzidine (100 μL, Surmodics Inc., Eden Prairie, MN, USA) was 
added to each well and then incubated at RT in the dark for 10 min. The 
reaction was stopped by the addition of phosphoric acid (100 μL) and 
the plate read at 450 nm using either Biotek Synergy HTX microplate 
reader or an automated liquid handler (Dynex Technologies, USA). 
2.3. Pilot study: sensitivity, specificity and cut-off co-efficient 
COVID-19 negative samples (n = 624, median 63 years of age, range 
18–98) and PCR-confirmed non-hospitalised, mild or moderate COVID- 
19 samples, ≥14 days post-symptom onset (n = 62, median 44 years of 
age, range 19–63) were analysed using manual and automated platforms 
using the human anti-IgGAM SARS-CoV-2 ELISA. The cut-off coefficient 
was determined, and the clinical study powered. 
3. Validation of the manufacturing process 
3.1. Sensitivity and specificity of the ELISA 
Sensitivity and specificity of the human anti-IgGAM SARS-CoV-2 
ELISA was assessed using COVID-19 negative serum samples (n = 359), 
and PCR-confirmed non-hospitalised, mild or moderate COVID-19 
samples (n = 73), ≥14 days post symptom onset, manually. 
3.2. Precision of the ELISA 
Precision was measured in accordance with the Clinical and Labo-
ratory Standards Institute guidelines EP12-A2 (Wayne, 2008). Forty 
COVID-19 negative serum samples replicates were spiked (<1%) with 
specific human monoclonal IgG1 anti- SARS-CoV-2 S glycoprotein 
(CR3022), at C5, C50 and C95. The C50 level, defined as a response of 
1.0, and at the C5- C95 interval, defined as being bounded by the 
response of 0.8–1.2 (+/− 20% of C50 response). The acceptable ranges 
for testing each of these three levels was defined as ±5% of the target 
response. Acceptance criteria was defined as, C5: ≥36 negatives out of 
40 replicates; C50: 14–26 positives out of 40 replicates; C95: ≥36 pos-
itives out of 40 replicates. The coefficient of variation (% CV) was 
additionally calculated for each cut-off. 
3.3. Interference with the ELISA 
Interference analysis was performed by spiking haemoglobin (2000 
mg/L), bilirubin (200 mg/L), triglyceride (3000 mg/L) into quintupli-
cate serum samples that were either antibody positive or antibody 
negative, (normal human serum spiked with/without CR3022). Controls 
were generated by spiking samples with equivalent volumes of saline. 
The assay was deemed to have passed the interference assessment if 
there was no change in the reportable value following the addition of the 
interfering agent. 
4. Cross reactivity of the ELISA with other respiratory diseases 
Cross-reactivity of the assay was assessed in patients with known 
respiratory diseases; endemic coronaviruses (n = 11), influenza and 
parainfluenza (n = 14), enteroviruses (n = 5), Epstein Bar virus (n = 4), 
adenovirus (n = 1) or respiratory syncytial virus (n = 4). Positive cross- 
reactivity was identified if the cut-off index value was ≥1. 
4.1. Stability of the ELISA 
Extremes of temperature stability was determined in triplicate 
Abbreviations 
DBS Dried Blood Spots 
ELISA Enzyme Linked Immunosorbent Assay 
PCR Polymerase Chain Reaction 
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2  
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following 24 h storage at either 37 ◦C or − 20 ◦C. Open vial stability was 
assessed over 15 days with 5 day interval sampling. Briefly, ELISAs were 
opened in parallel and components re-capped and stored at 4 ◦C. 
4.2. Dried blood spot versus serum samples 
Paired DBS and serum samples (49 PCR-confirmed non-hospitalised, 
mild or moderate COVID-19 samples and 32 COVID-19 negative sam-
ples) collected at the same time, were assayed using the human anti- 
IgGAM SARS-CoV-2 ELISA. Capillary blood samples (50 μL per spot) 
were collected onto 226 grade forensic collection cards (Ahlstrom 
Munksjo, Germany). Individual 12 mm diameter pre-perforated DBS 
spots were isolated using a sterile pipette tip and placed into a universal 
tube at a ratio of one spot to 250 μL 0.05% PBS Tween-20 (Sigma). Tubes 
were briefly vortexed and incubated overnight at room temperature. 
DBS eluate was subsequently harvested into a microtube and centrifuged 
at 10,600 ×g for 10 min at room temperature and stored at 4 ◦C until 
used (Morley et al., 2020). DBS samples were applied to the assay at a 1 
in 4 dilution, resulting in a 1 in 40 overall dilution. Results were ana-
lysed using Bland Altman, Passing-Bablok and Cohen’s kappa statistic. 
4.3. Clinical study 
COVID-19 negative (n = 426) and PCR-confirmed non-hospitalised, 
mild or moderate COVID-19 samples (n = 226), ≥14 days post symptom 
onset, were assayed using the human anti-IgGAM SARS-CoV-2 ELISA on 
the automated platform. 
4.4. Statistics 
All graphs and statistical analysis were generated using Graph Pad 
Prism statistical software version 5.04 or Analyse-it® for Microsoft 
Excel. Assay validation sensitivity, specificity and precision (95% CI and 
% CVs) were calculated using Analyse-it. The matrix comparison was 
analysed using Bland-Altman, Passing Bablok and Cohen’s kappa sta-
tistics (Analyse-it). To achieve an expectant 98%, minimum 93%, 
sensitivity in the clinical study, a 90% power with 5% alpha error was 
determined from the pilot study. A p < 0.05 was considered statistically 
significant. 
5. Results 
5.1. Pilot study to determine sensitivity, specificity and cut-off co-efficient 
of the ELISA 
The pilot study with 624 COVID-19 negative and 62 PCR-confirmed 
non-hospitalised, mild or moderate COVID-19 samples, which were at 
least 14 days from symptom onset were analysed on the human anti- 
IgGAM SARS-CoV-2 ELISA. The ELISA output result was reported as a 
ratio to the cut-off calibrator (run in parallel) and multiplied by the cut- 
off co-efficient. The cut-off coefficient was determined from the pilot 
study, results were reported as the sample to plate ratio (samples optical 
density at 450 nm /cut off calibrator optical density at 450 nm). From 
the sample to plate ratio results, sensitivity and specificity was calcu-
lated and the cut-off calibrator co-efficient determined. This would 
maintain batch-to-batch consistency and was defined here as 1.15. A 
sensitivity of 98.5% (95% CI 91.8–100%) and specificity of 97.6% (95% 
CI 96.1–98.7%) was achieved, (Table 1 & Fig. 1). 
From the pilot study a minimum of 167 PCR-confirmed non-hospi-
talised, mild or moderate COVID-19 samples, ≥14 days post symptom 
onset would be required for the clinical study to determine whether the 
ELISA test delivered the expected sensitivity of 98% (minimum of 93%) 
Table 1 
Sensitivity and specificity of the pilot, validation and clinical study using the human anti-IgGAM SARS-CoV-2 ELISA. Assay assessed using COVID-19 negative samples 
and PCR-confirmed non-hospitalised, mild or moderate COVID-19 samples, ≥14 days post symptom onset.  
Pilot, validation & clinical studies: specificity & sensitivity 
Study Category Number Positive Negative Specificity (95% CI) Sensitivity (95% CI) 
Pilot Study (manual & automated) COVID-19 negative 624 15 609 97.6 (96.1–98.5) 98.5% (91.4–99.7) 
PCR confirmed, non-hospitalised COVID-19 positive 62 61 1 
Validation Study (manual) COVID-19 negative 359 6 353 98.3 (96.4–99.4) 98.6 (92.6–100.0) 
PCR confirmed, non-hospitalised COVID-19 positive 73 72 1 
Clinical Study (automated) COVID-19 negative 426 7 419 98.4 (96.6–99.3) 94.7 (90.9–97.2) 
PCR confirmed, non-hospitalised COVID-19 positive 226 214 12  
Fig. 1. The distribution of responses and sensitivity and specificity of the 
human anti-IgGAM SARS-CoV-2 ELISA. 
The cumulative standard normal distribution of optical densities of (A) COVID- 
19 negative samples (n = 624, blue) and PCR-confirmed non-hospitalised, mild 
or moderate COVID-19 samples, ≥14 days post symptom onset (n = 62, red). 
(B) ROC curve of sensitivity (98.5%, 95% CI 91.4–99.7%) and specificity 
(97.6%, 95% CI 96.1–98.5%). 
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with an alpha error of 5% and power of 90%. 
5.2. Validation of the manufacturing process 
Sensitivity and specificity were assessed in COVID-19 negative 
samples (n = 359) and PCR-confirmed non-hospitalised, mild or mod-
erate COVID-19 samples, ≥14 days post symptom onset (n = 73). 
COVID-19 negative samples were identified as negative for SARS-CoV-2 
antibodies when assay results were less than 1 and PCR confirmed 
COVID-19 positive samples were identified as positive when the assay 
results were greater than 1, using the human anti-IgGAM SARS-CoV-2 
ELISA (Fig. 2). This resulted in an assay sensitivity of 98.6% (95% CI 
92.6–100.0%) and specificity of 98.3% (95% CI 96.4–99.4%), (Table 1). 
Assay precision was assessed in 40 replicates by following the CLSI 
EP12-A2 guidelines to determine whether the C5 to C95 response range 
(range of responses at which imprecision around the C50 occurs) falls 
within 20% of C50. The precision of the assay was demonstrated at +/−
20% of C50 as C5 gave a mean of 0.77 (40 negatives out of 40 replicates, 
4.56% CV), C50 gave a mean of 1.02 (25 positives out of 40 replicates, 
5.07% CV) and C95 gave a mean of 1.13 (40 positives out of 40 repli-
cates, 3.97% CV), (Fig. 3). 
Generally, no change in overall result outcome were observed 
following potential analytical interference from increased haemoglobin, 
bilirubin or triglyceride concentrations, (Fig. 4 A). Two samples con-
taining elevated bilirubin did result in increased result outputs, how-
ever, only 1 sample resulted in a change of response. Assessing cross- 
reactivity with other human viruses and coronaviruses, 39 samples 
tested negative covering 8 disease categories, (Fig. 4 B). Kit components 
were stable once opened for 15 days and for one day at extremes of 
temperature (Fig. 4 C & D). 
5.3. Dried blood spot versus serum samples 
Responses were measured in 81 matched serum and DBS samples, 
with unknown PCR status. A strong correlation was observed between 
the two matrices when assessed using the ELISA (Passing Bablok r =
0.959, y = 0.16–0.91×), with a mean positive bias towards the DBS 
compared to serum (Bland Altman 0.05, 95% CI -0.773 to 0.679), 
(Fig. 5). An almost perfect agreement, 0.83 (Cohen’s kappa) was 
observed between the two sampling matrices. 
5.4. Clinical study 
The assay was validated in clinical samples from an independent 
group of COVID-19 negative samples (n = 426) and PCR-confirmed non- 
hospitalised, mild or moderate COVID-19 samples, ≥14 days post 
symptom onset (n = 226). The sensitivity of the anti-IgGAM SARS-CoV-2 
ELISA in this cohort was 94.7% (95% CI, 90.9–97.2%) and specificity 
98.4% (95% CI, 96.6–99.3%), (Fig. 6 & Table 1). 
6. Discussion 
Seroepidemiological studies are essential in understanding 
population-level exposure to SARS-CoV-2, determining correlates of 
protection from re-infection and guiding public health policy. The ac-
curacy of such studies is determined by the performance characteristics 
of the immunoassay used to determine serostatus. Using samples derived 
from non-hospitalised adults with mild or moderate COVID-19 disease 
we developed a highly sensitive (98.6%) and specific (98.3%) anti- 
IgGAM SARS-CoV-2 ELISA. The assay showed no cross reactivity with 
endemic coronaviruses or other respiratory diseases, even though 30% 
of common colds are caused by alpha and beta coronaviruses (Paules 
et al., 2020). 
By validating this assay using samples from non-hospitalised adults, 
we demonstrate the human anti-IgGAM SARS-CoV-2 ELISA to be a 
reliable assay for future seroepidemiological studies of the general 
population, the majority of whom will not require hospitalisation 
following infection with SARS-CoV-2. Current testing in the community 
has been problematic due to the inadequate sensitivities and specificities 
of current point of care tests in non-hospitalised patients with mild or 
moderate disease (Deeks et al., 2020). 
The assay targets nearly the entirety of the trimeric spike protein, 
and thereby offers a greater range of epitopes, as reports suggest neu-
tralising antibodies to SARS-CoV-2 are not only targeted towards the 
receptor binding domain but also elicit high affinity and cross-reactivity 
to other sites across the spike (Wrapp et al., 2020; Brouwer et al., 2020; 
Rogers et al., 2020; Chi et al., 2020; Liu et al., 2020). Faustini et al. 
compared the receptor binding domain, S1 domain and nucleocapsid 
and although these targets were excellent at detecting antibodies in 
severe COVID-19 patients, they were not as effective when antibody 
concentrations were more limited (Faustini et al., 2020). Serological 
assays have been developed to detect the antibody response present in 
severe disease (hospitalised patients). This assay was therefore devel-
oped and tested in non-hospitalised adults, at least 14 days post- 
symptom onset, with mild or moderate COVID-19, where the antibody 
Fig. 2. IgGAM response in COVID-19 negative (n = 359) and PCR-confirmed 
non-hospitalised, mild or moderate COVID-19 samples, ≥14 days post symp-
tom onset (n = 73). 
A sensitivity and specificity of 98.6% (95% CI 92.6–100%) and 98.3% (95% CI 
96.4–99.4%), respectively, was reported using an assay cut-off of 1.0. 
Fig. 3. Precision of the human anti-IgGAM SARS CoV-2 ELISA. 
Precision was measured using clinical and lab standards guidelines EP12-A2 in 
40 replicates and assessed at clinical cut-offs C5, C50 and C95. The mean and 
coefficient of variation (%) was calculated for each clinical cut-off. 
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Fig. 4. Stability and cross reactivity of antibody positive or anti-
body negative serum samples on the anti-IgGAM SARS CoV-2 
ELISA. 
The assay was assessed for (A) interfering substances, bilirubin, 
haemoglobin and triglyceride (n = 5 replicates per test) in anti-
body positive or antibody negative serum samples; and (B) eval-
uated for cross reactivity with human viruses and other endemic 
coronaviruses (n = 39). Additionally, the kit components were 
tested for (C) stability at extreme temperatures (-20 ◦C, 4 ◦C and 
37 ◦C) (n = 3) and (D) stability once opened (n = 4).   
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concentrations are much lower than in hospitalised patients with severe 
disease (Deeks et al., 2020; Faustini et al., 2020; Sun et al., 2020). 
The assay measures anti-IgG, IgA and IgM as reports suggest an 
asynchronous serological response. In adults, Seow et al. showed that 
the kinetics of IgGAM only occurred synchronously in 50% patients, 
with 9.7% developing either IgG, A and M first, 9.7% developing IgM 
and IgG together, 3% developing IgA and IgM together, and 3% devel-
oping IgA and IgG together (Seow et al., 2020). Valdivia et al. reported 
that 3.5% asymptomatic patients presented with IgM while negative for 
IgG (Valdivia et al., 2021). Long et al. showed that seroconversion for 
IgG and IgM occurred synchronously or simultaneously (Long et al., 
2020). Additionally, the longevity of the antibody responses is still 
under investigation. Studies by Iyer et al. showed that adult patients 
were IgA and IgM seronegative by 51 and 47 days, respectively, while 
IgG persisted to the end of their evaluation period (75 days) (Iyer et al., 
2020). Gudbjartsson, reported IgG persisting without reduction up to 4 
months after diagnosis (Gudbjartsson et al., 2020). A potential limita-
tion associated with measuring the combined IgGAM result to that of IgG 
alone is that the IgA and IgM antibody response will reduce as the im-
mune response prevails, therefore measurement of IgG alone could be 
indicative of the longer term response. 
This assay benefits by being able to assess SARS-CoV-2 IgGAM an-
tibodies in both mild and moderate disease, while also being compatible 
with remote sampling. Here, antibodies obtained from DBSs were shown 
to correlate well with serum results. DBSs are readily used in analytical 
assays for viruses such as those for human immunodeficiency virus 
(HIV) and hepatitis B and C (Freeman et al., 2018; Ross et al., 2013; 
Cassol et al., 1992) They are also frequently used for other applications 
such as screening of neonates, metabolic profiling, pharmacokinetic, 
forensic and environmental assays (Freeman et al., 2018; Gupta and 
Mahajan, 2018; Bjorkesten et al., 2017). The major advantages with 
using DBS’s include: the requirement for a smaller volume of blood, 
reduced risk of potential bacterial contamination, non-invasive blood 
collection, easy delivery-to- test centre, low cost and stability for pro-
longed periods of time with minimal deterioration of analytes (Morley 
et al., 2020; Freeman et al., 2018; Gupta and Mahajan, 2018). The 
additional advantage in the current COVID-19 pandemic include, 
ensuring patients do not have to attend hospitals and sites with greater 
risk of infection. Rickman et al. reported in a major London Teaching 
Hospital 15% of in-patient COVID-19 cases developed as a result of 
varied transmission routes within the hospital (Rickman et al., 2020) 
and Meredith et al. also reported strong and plausible epidemiological 
links following the identification of 35 clusters of identical viruses 
Fig. 5. Comparison of the anti-IgGAM SARS-CoV-2 ELISA response in DBS and 
serum samples. 
The response was measured in 81 DBS and serum matched samples. A com-
parison between the two collection methods were assessed using (A) Passing- 
Bablok analysis (r = 0.959, y = 0.16 + 0.91×) and (B) Bland-Altman analysis 
(central line demonstrates mean difference and broken lines shows the limits of 
agreement, − 0.76 to 0.86). 
Fig. 6. Clinical study. 
The cumulative standard normal distribution of (A) COVID-19 negative samples 
(n = 426, blue) and PCR confirmed, mild or moderate COVID-19 positive 
samples, ≥14 days post symptom onset samples (n = 226, red). (B) ROC curve 
of sensitivity (94.7%, 95% CI 90.9–97.2%) and specificity (98.4%, 95% 
CI 96.6–99.3%). 
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associated among patients in their hospital (Meredith et al., 2020). 
Therefore, when using DBSs, the test becomes accessible to all, including 
those that are vulnerable and those beyond developed countries. 
In conclusion, utilising the trimeric spike protein and measuring IgG, 
IgA and IgM simultaneously, the human anti-IgGAM SARS-CoV-2 ELISA 
assay provides accurate and sensitive detection of antibody responses to 
SARS-CoV-2 in adults with mild or moderate disease. The use of dried 
blood spots makes this assay more accessible to the wider community. 
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